First Light Asset Management LLC Buys 117,137 Shares of ADMA Biologics Inc $ADMA

First Light Asset Management LLC increased its position in ADMA Biologics Inc (NASDAQ:ADMA) by 12.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,069,233 shares of the biotechnology company’s stock after buying an additional 117,137 shares during the period. ADMA Biologics accounts for approximately 1.5% of First Light Asset Management LLC’s investment portfolio, making the stock its 25th biggest holding. First Light Asset Management LLC owned about 0.45% of ADMA Biologics worth $15,675,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. grew its stake in ADMA Biologics by 8.4% in the second quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock valued at $83,966,000 after acquiring an additional 358,627 shares during the period. Thrivent Financial for Lutherans increased its holdings in shares of ADMA Biologics by 24.9% during the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after acquiring an additional 826,415 shares in the last quarter. Ranger Investment Management L.P. raised its position in shares of ADMA Biologics by 49.1% during the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after purchasing an additional 786,865 shares during the period. WINTON GROUP Ltd raised its position in shares of ADMA Biologics by 302.8% during the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock worth $4,968,000 after purchasing an additional 205,094 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new position in shares of ADMA Biologics in the 3rd quarter worth $877,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $15.15 on Monday. ADMA Biologics Inc has a twelve month low of $13.76 and a twelve month high of $25.67. The stock’s 50 day moving average price is $16.63 and its 200-day moving average price is $16.70. The company has a market capitalization of $3.61 billion, a PE ratio of 25.25 and a beta of 0.51. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. The company had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.ADMA Biologics’s quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.46 earnings per share. On average, equities analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on ADMA. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $32.00.

Insiders Place Their Bets

In other ADMA Biologics news, Director Steve Elms bought 7,000 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was purchased at an average cost of $15.67 per share, with a total value of $109,690.00. Following the transaction, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.70% of the stock is owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.